Javascript must be enabled to continue!
Possible mechanisms of the hypoglycaemic effect of artesunate: Gender implication
View through CrossRef
Abstract
Background
Artesunate is an antimalarial drug that affects glucose homeostasis but the mechanism of its glucose-modulating effect is not fully understood especially with gender implication, which is the information this study sought to provide.
Methods
Twenty-five (25) male and 25 female rats were separately and blindly allocated into five identical groups (n = 5/group). Group I (control) received 0.2 ml/kg distilled water. Groups II and III both received 2.90 mg/kg artesunate on day one, but 1.45 mg/kg from day two till day five and day fifteen respectively. Groups IV and V both received 8.70 mg/kg artesunate on day one, but 4.35 mg/kg artesunate from day two till day five and day fifteen respectively.
Results
In male rats, the blood glucose was reduced by low and high doses of artesunate at 5 days but increased by high dose at 15 days. Glucose was reduced in female rats but unchanged in male rats by low dose artesunate at 15 days. Artesunate increased glycogen concentration at short duration which normalised at long duration in both genders. Artesunate increased G6P concentration only in male rats at 15 days but reduced G6Pase activity in male and female rats (except in those that received low and high doses of artesunate for 15 days). Artesunate increased insulin only in male rats treated with low dose artesunate for 5 days. Artesunate increased cortisol concentration in male but reduced it in female rats. Artesunate decreased glucagon concentration except in female rats treated with high dose for 5 days. Artesunate increased oestrogen concentration in male rats that received low dose artesunate for 5 days but reduced it in female rats that received high dose for 15 days. Except in male rats that received high dose of artesunate for 15 days where testosterone was increased, artesunate did not affect testosterone concentration in all other male and female groups
Conclusions
The present study suggests that artesunate causes reduction in plasma glucose by reducing plasma glucagon concentrations and inhibiting liver glycogenolysis via inhibition of G6Pase activity in both sexes. In addition, increase in plasma insulin concentration contributed to the reduction in blood glucose caused by artesunate in male but not female rats; and artesunate-induced increase in G6P, a substrate for G6PD, could enhance NADPH generation and antioxidant enzyme activation in male rats.
Springer Science and Business Media LLC
Title: Possible mechanisms of the hypoglycaemic effect of artesunate: Gender implication
Description:
Abstract
Background
Artesunate is an antimalarial drug that affects glucose homeostasis but the mechanism of its glucose-modulating effect is not fully understood especially with gender implication, which is the information this study sought to provide.
Methods
Twenty-five (25) male and 25 female rats were separately and blindly allocated into five identical groups (n = 5/group).
Group I (control) received 0.
2 ml/kg distilled water.
Groups II and III both received 2.
90 mg/kg artesunate on day one, but 1.
45 mg/kg from day two till day five and day fifteen respectively.
Groups IV and V both received 8.
70 mg/kg artesunate on day one, but 4.
35 mg/kg artesunate from day two till day five and day fifteen respectively.
Results
In male rats, the blood glucose was reduced by low and high doses of artesunate at 5 days but increased by high dose at 15 days.
Glucose was reduced in female rats but unchanged in male rats by low dose artesunate at 15 days.
Artesunate increased glycogen concentration at short duration which normalised at long duration in both genders.
Artesunate increased G6P concentration only in male rats at 15 days but reduced G6Pase activity in male and female rats (except in those that received low and high doses of artesunate for 15 days).
Artesunate increased insulin only in male rats treated with low dose artesunate for 5 days.
Artesunate increased cortisol concentration in male but reduced it in female rats.
Artesunate decreased glucagon concentration except in female rats treated with high dose for 5 days.
Artesunate increased oestrogen concentration in male rats that received low dose artesunate for 5 days but reduced it in female rats that received high dose for 15 days.
Except in male rats that received high dose of artesunate for 15 days where testosterone was increased, artesunate did not affect testosterone concentration in all other male and female groups
Conclusions
The present study suggests that artesunate causes reduction in plasma glucose by reducing plasma glucagon concentrations and inhibiting liver glycogenolysis via inhibition of G6Pase activity in both sexes.
In addition, increase in plasma insulin concentration contributed to the reduction in blood glucose caused by artesunate in male but not female rats; and artesunate-induced increase in G6P, a substrate for G6PD, could enhance NADPH generation and antioxidant enzyme activation in male rats.
Related Results
Sfrps Family Invovled in Growth Inhibition of K562 Cells Induced by Artesunate
Sfrps Family Invovled in Growth Inhibition of K562 Cells Induced by Artesunate
Abstract
Abstract 5015
Introduction:
Studies have shown that abnormal activation of wnt signaling pathway is clos...
Association between hypoglycaemic events and fall‐related fractures in Medicare‐covered patients with type 2 diabetes
Association between hypoglycaemic events and fall‐related fractures in Medicare‐covered patients with type 2 diabetes
Aims:
This retrospective observational study examined the association between International Classification of Diseases, Ninth Revision, Clinical Modification (I...
Amelioration of Aluminium Chloride (AlCl3) Induced Neurotoxicity by Combination of Rivastigmine and Memantine with Artesunate in Albino Wistar Rats
Amelioration of Aluminium Chloride (AlCl3) Induced Neurotoxicity by Combination of Rivastigmine and Memantine with Artesunate in Albino Wistar Rats
Alzheimer’s disease (AD) is an age-related progressive disorder characterized by neurodegeneration and accumulation of abnormal proteins. Artesunate, an anti-malarial drug has rece...
Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in the Treatment of Acute Uncomplicated Malaria in Children in South-West Nigeria: An open- labelled randomized controlled trial
Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in the Treatment of Acute Uncomplicated Malaria in Children in South-West Nigeria: An open- labelled randomized controlled trial
Abstract
Background: Declining responsiveness to artemether-lumefantrine (AL), the ACT of choice since 2005, has been reported in Nigeria. Pyronaridine-artesunate (PA) is a...
Artesunate-tinospora combination treatment decreases nuclear factor kappa-B and intercellular adhesion molecule-1 expression in mouse malarial models
Artesunate-tinospora combination treatment decreases nuclear factor kappa-B and intercellular adhesion molecule-1 expression in mouse malarial models
Background<br />Cerebral malaria is a severe form of malaria caused by brain ischemia. Artesunate, an artemisinin derivative, is the standard WHO therapy for severe malaria. ...
Development of colorimetric method for the assay of artesunate using 4-nitrobenzaldehyde
Development of colorimetric method for the assay of artesunate using 4-nitrobenzaldehyde
Purpose: Artesunate is one of the artemisinin derivatives that is commonly used in combination with some anti-malarials as artemisinin-based combination therapies. High performance...
Suspected
Plasmodium falciparum
resistance to artesunate in Cameroon: A case report
Suspected
Plasmodium falciparum
resistance to artesunate in Cameroon: A case report
Malaria in pregnancy is associated with adverse maternal and perinatal outcomes. The first-line treatment for severe malaria in the second and third trimesters of pregnancy is pare...
PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
Abstract
Objectives
The objective of this retrospective analysis was to compare the occurrence of Level 1 hypoglycaemia, Level 2...

